6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Bullous	JJ	bullous	bullous	bullou	N	B-AdverseReaction
and	CC	and	and	and	N	O
Exfoliative	JJ	exfoliative	exfoliative	exfoli	N	B-AdverseReaction
Skin	NNP	skin	skin	skin	N	I-AdverseReaction
Disorders	NNP	disorders	disorder	disord	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
Lung	NNP	lung	lung	lung	N	I-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Keratitis	NNP	keratitis	keratitis	kerat	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
acneiform	NN	acneiform	acneiform	acneiform	N	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
paronychia	NN	paronychia	paronychia	paronychia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Boehringer	NNP	boehringer	boehringer	boehring	N	O
Ingelheim	NNP	ingelheim	ingelheim	ingelheim	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
(	(	(	(	(	N	O
800	CD	800	800	800	N	O
)	)	)	)	)	N	O
542	CD	542	542	542	N	O
-	:	-	-	-	N	O
6257	CD	6257	6257	6257	N	O
or	CC	or	or	or	N	O
(	(	(	(	(	N	O
800	CD	800	800	800	N	O
)	)	)	)	)	N	O
459	CD	459	459	459	N	O
-	:	-	-	-	N	O
9906	CD	9906	9906	9906	N	O
TTY	NNP	tty	tty	tti	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
orwww	NN	orwww	orwww	orwww	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
data	NN	data	data	data	N	O
from	IN	from	from	from	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
3800	CD	3800	3800	3800	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
2135	CD	2135	2135	2135	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
at	IN	at	at	at	N	O
or	CC	or	or	or	N	O
above	IN	above	above	abov	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Controlled	VBN	controlled	controlled	control	N	O
Study	NNP	study	study	studi	N	O
The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
below	IN	below	below	below	N	O
reflect	JJ	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
229	CD	229	229	229	N	O
EGFR	NNP	egfr	egfr	egfr	N	O
-	:	-	-	-	N	O
TKI	NNP	tki	tki	tki	N	O
naive	JJ	naive	naive	naiv	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
EGFR	NNP	egfr	egfr	egfr	N	O
mutation	NN	mutation	mutation	mutat	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
,	,	,	,	,	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
,	,	,	,	,	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
squamous	JJ	squamous	squamous	squamou	N	O
,	,	,	,	,	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
40	CD	40	40	40	N	O
mg	JJ	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
until	IN	until	until	until	N	O
documented	JJ	documented	documented	document	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
or	CC	or	or	or	N	O
intolerance	NN	intolerance	intolerance	intoler	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
111	CD	111	111	111	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
cisplatin	NN	cisplatin	cisplatin	cisplatin	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
500	CD	500	500	500	N	O
mg	NN	mg	mg	mg	N	O
m2	NN	m2	m2	m2	N	O
followed	VBD	followed	followed	follow	N	O
after	IN	after	after	after	N	O
30	CD	30	30	30	N	O
minutes	NNS	minutes	minute	minut	N	O
by	IN	by	by	by	N	O
cisplatin	NN	cisplatin	cisplatin	cisplatin	N	O
75	CD	75	75	75	N	O
mg	NN	mg	mg	mg	N	O
m2	NN	m2	m2	m2	N	O
every	DT	every	every	everi	N	O
three	CD	three	three	three	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
maximum	NN	maximum	maximum	maximum	N	O
of	IN	of	of	of	N	O
six	CD	six	six	six	N	O
treatment	NN	treatment	treatment	treatment	N	O
courses	NNS	courses	course	cours	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
exposure	NN	exposure	exposure	exposur	N	O
was	VBD	was	wa	wa	N	O
11.0	CD	11.0	11.0	11.0	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
and	CC	and	and	and	N	O
3.4	CD	3.4	3.4	3.4	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
cisplatin	NN	cisplatin	cisplatin	cisplatin	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
trial	NN	trial	trial	trial	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
61	CD	61	61	61	N	O
years	NNS	years	year	year	N	O
;	:	;	;	;	N	O
61%	CD	61%	61%	61%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
60%	CD	60%	60%	60%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
cisplatin	NN	cisplatin	cisplatin	cisplatin	N	O
arm	NN	arm	arm	arm	N	O
were	VBD	were	were	were	N	O
younger	JJR	younger	younger	younger	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
64%	CD	64%	64%	64%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
and	CC	and	and	and	N	O
67%	CD	67%	67%	67%	N	O
of	IN	of	of	of	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
cisplatin	NN	cisplatin	cisplatin	cisplatin	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
.	.	.	.	.	N	O

More	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
two	CD	two	two	two	N	O
-	:	-	-	-	N	O
thirds	NNS	thirds	third	third	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
from	IN	from	from	from	N	O
Asia	NNP	asia	asia	asia	N	O
(	(	(	(	(	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
70%	CD	70%	70%	70%	N	O
;	:	;	;	;	N	O
pemetrexed	VBN	pemetrexed	pemetrexed	pemetrex	N	O
cisplatin	VBP	cisplatin	cisplatin	cisplatin	N	O
72%	CD	72%	72%	72%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
29%	CD	29%	29%	29%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
were	VBD	were	were	were	N	O
diarrhea	NNS	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.6%	CD	6.6%	6.6%	6.6%	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
4.8%	CD	4.8%	4.8%	4.8%	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
dyspnea	VB	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
each	DT	each	each	each	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
included	VBD	included	included	includ	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.43%	CD	0.43%	0.43%	0.43%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.43%	CD	0.43%	0.43%	0.43%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
57%	CD	57%	57%	57%	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
were	VBD	were	were	were	N	O
diarrhea	NNS	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
acne	NN	acne	acne	acn	Y	B-AdverseReaction
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
paronychia	FW	paronychia	paronychia	paronychia	Y	B-AdverseReaction
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
14.0%	CD	14.0%	14.0%	14.0%	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
paronychia	NN	paronychia	paronychia	paronychia	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
excluded	VBD	excluded	excluded	exclud	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
left	NN	left	left	left	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
ejection	NN	ejection	ejection	eject	N	O
fraction	NN	fraction	fraction	fraction	N	O
(	(	(	(	(	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
i	JJ	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
below	IN	below	below	below	N	O
the	DT	the	the	the	N	O
institutional	JJ	institutional	institutional	institut	N	O
lower	JJR	lower	lower	lower	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
at	IN	at	at	at	N	O
screening	NN	screening	screening	screen	N	O
and	CC	and	and	and	N	O
every	DT	every	every	everi	N	O
9	CD	9	9	9	N	O
weeks	NNS	weeks	week	week	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pemetrexed	JJ	pemetrexed	pemetrexed	pemetrex	N	O
cisplatin	NN	cisplatin	cisplatin	cisplatin	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
;	:	;	;	;	N	O
n	CC	n	n	n	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
(	(	(	(	(	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
left	VBD	left	left	left	N	B-AdverseReaction
ventricular	JJ	ventricular	ventricular	ventricular	N	I-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
dilation	NN	dilation	dilation	dilat	N	I-AdverseReaction
;	:	;	;	;	N	O
all	DT	all	all	all	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
chemotherapy	VB	chemotherapy	chemotherapy	chemotherapi	Y	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
;	:	;	;	;	N	O
n	CC	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
table	NN	table	table	tabl	N	O
except	IN	except	except	except	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
(	(	(	(	(	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
[	NNP	[	[	[	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
])	NN	])	])	])	N	O
were	VBD	were	were	were	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
1	CD	1	1	1	N	O
Includes	NNP	includes	includes	includ	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction
,	,	,	,	,	N	O
mucosal	JJ	mucosal	mucosal	mucos	N	B-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
,	,	,	,	,	N	O
mouth	JJ	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
mucosa	NN	mucosa	mucosa	mucosa	N	I-AdverseReaction
erosion	NN	erosion	erosion	eros	N	I-AdverseReaction
,	,	,	,	,	N	O
mucosal	JJ	mucosal	mucosal	mucos	N	B-AdverseReaction
erosion	NN	erosion	erosion	eros	N	I-AdverseReaction
,	,	,	,	,	N	O
mucosal	JJ	mucosal	mucosal	mucos	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
2	CD	2	2	2	N	O
Includes	NNP	includes	includes	includ	N	O
group	NN	group	group	group	N	O
of	IN	of	of	of	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
,	,	,	,	,	N	O
acne	NN	acne	acne	acn	Y	B-AdverseReaction
,	,	,	,	,	N	O
acne	JJ	acne	acne	acn	Y	B-AdverseReaction
pustular	NN	pustular	pustular	pustular	N	I-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
acneiform	NN	acneiform	acneiform	acneiform	N	I-AdverseReaction
3	CD	3	3	3	N	O
Includes	NNP	includes	includes	includ	N	O
paronychia	NN	paronychia	paronychia	paronychia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nail	JJ	nail	nail	nail	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nail	JJ	nail	nail	nail	N	B-AdverseReaction
bed	NN	bed	bed	bed	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

GILOTRIFn	NN	gilotrifn	gilotrifn	gilotrifn	N	O

229	CD	229	229	229	N	O
Pemetrexed	NNP	pemetrexed	pemetrexed	pemetrex	N	O
Cisplatinn	NNP	cisplatinn	cisplatinn	cisplatinn	N	O
111	CD	111	111	111	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
96	CD	96	96	96	N	O
15	CD	15	15	15	N	O
23	CD	23	23	23	N	O
2	CD	2	2	2	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
1	CD	1	1	1	N	O
71	CD	71	71	71	N	O
9	CD	9	9	9	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
25	CD	25	25	25	N	O
4	CD	4	4	4	N	O
68	CD	68	68	68	N	O
4	CD	4	4	4	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
23	CD	23	23	23	N	O
4	CD	4	4	4	N	O
47	CD	47	47	47	N	O
3	CD	3	3	3	N	O

Cheilitis	NN	cheilitis	cheilitis	cheiliti	Y	B-AdverseReaction
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
Dermatitis	NNP	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
acneiform	VBD	acneiform	acneiform	acneiform	N	I-AdverseReaction
2	CD	2	2	2	N	O
90	CD	90	90	90	N	O
16	CD	16	16	16	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	VBD	skin	skin	skin	N	I-AdverseReaction
31	CD	31	31	31	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Paronychia	NNP	paronychia	paronychia	paronychia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
58	CD	58	58	58	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
29	CD	29	29	29	N	O
4	CD	4	4	4	N	O
55	CD	55	55	55	N	O
4	CD	4	4	4	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Epistaxis	NNP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Rhinorrhea	NNP	rhinorrhea	rhinorrhea	rhinorrhea	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Eye	NN	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O

Conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
Investigations	NNP	investigations	investigation	investig	N	O
SOC	NNP	soc	soc	soc	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

1	CD	1	1	1	N	O
Includes	NNP	includes	includes	includ	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
decreasedSOC	NN	decreasedsoc	decreasedsoc	decreasedsoc	N	I-AdverseReaction
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O

GILOTRIFn	NN	gilotrifn	gilotrifn	gilotrifn	N	O

229	CD	229	229	229	N	O
Pemetrexed	NNP	pemetrexed	pemetrexed	pemetrex	N	O
Cisplatinn	NNP	cisplatinn	cisplatinn	cisplatinn	N	O
111	CD	111	111	111	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grades	VBZ	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grades	VBZ	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
11	CD	11	11	11	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
8	CD	8	8	8	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
:	:	:	:	:	N	O
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
and	CC	and	and	and	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
not	RB	not	not	not	N	O
responsive	JJ	responsive	responsive	respons	N	O
to	TO	to	to	to	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheal	NN	diarrheal	diarrheal	diarrheal	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Bullous	JJ	bullous	bullous	bullou	N	O
and	CC	and	and	and	N	O
Exfoliative	JJ	exfoliative	exfoliative	exfoli	N	O
Skin	NNP	skin	skin	skin	N	B-AdverseReaction
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
bullous	JJ	bullous	bullous	bullou	N	I-AdverseReaction
,	,	,	,	,	N	O
blistering	NN	blistering	blistering	blister	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
exfoliating	VBG	exfoliating	exfoliating	exfoli	N	I-AdverseReaction
lesions	NNS	lesions	lesion	lesion	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.15%	CD	0.15%	0.15%	0.15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinue	NN	discontinue	discontinue	discontinu	N	O
for	IN	for	for	for	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	VBG	threatening	threatening	threaten	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
and	CC	and	and	and	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Occurs	VBN	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
for	IN	for	for	for	N	O
acute	JJ	acute	acute	acut	N	O
onset	NN	onset	onset	onset	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
if	IN	if	if	if	N	O
ILD	NNP	ild	ild	ild	N	O
is	VBZ	is	is	is	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
occurs	VBZ	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
0.18%	CD	0.18%	0.18%	0.18%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
with	IN	with	with	with	N	O
periodic	JJ	periodic	periodic	period	N	O
liver	NN	liver	liver	liver	N	O
testing	NN	testing	testing	test	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
liver	JJ	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Keratitis	NN	keratitis	keratitis	kerat	Y	B-AdverseReaction
:	:	:	:	:	N	O
Occurs	NNP	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
for	IN	for	for	for	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
for	IN	for	for	for	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
ulcerative	JJ	ulcerative	ulcerative	ulcer	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
highly	RB	highly	highly	highli	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
resulted	VBN	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
;	:	;	;	;	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
96%	CD	96%	96%	96%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
229	CD	229	229	229	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
15%	CD	15%	15%	15%	N	O
was	VBD	was	wa	wa	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
consequence	NN	consequence	consequence	consequ	N	O
of	IN	of	of	of	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
6.1%	CD	6.1%	6.1%	6.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
,	,	,	,	,	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
prolonged	VBN	prolonged	prolonged	prolong	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
lasting	VBG	lasting	lasting	last	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
48	CD	48	48	48	N	O
hours	NNS	hours	hour	hour	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
until	IN	until	until	until	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	O
resolves	NNS	resolves	resolve	resolv	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
resume	VB	resume	resume	resum	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Provide	VB	provide	provide	provid	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheal	NN	diarrheal	diarrheal	diarrheal	N	O
agent	NN	agent	agent	agent	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
loperamide	NN	loperamide	loperamide	loperamid	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
self	NN	self	self	self	N	O
-	:	-	-	-	N	O
administration	NN	administration	administration	administr	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
and	CC	and	and	and	N	O
instruct	NN	instruct	instruct	instruct	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
continue	VB	continue	continue	continu	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheal	NN	diarrheal	diarrheal	diarrheal	N	O
therapy	NN	therapy	therapy	therapi	N	O
until	IN	until	until	until	N	O
loose	JJ	loose	loose	loos	N	O
bowel	NN	bowel	bowel	bowel	N	O
movements	NNS	movements	movement	movement	N	O
cease	VB	cease	cease	ceas	N	O
for	IN	for	for	for	N	O
12	CD	12	12	12	N	O
hours	NNS	hours	hour	hour	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Bullous	JJ	bullous	bullous	bullou	N	O
and	CC	and	and	and	N	O
Exfoliative	JJ	exfoliative	exfoliative	exfoli	N	O
Skin	NNP	skin	skin	skin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
characterized	VBN	characterized	characterized	character	N	O
by	IN	by	by	by	N	O
bullous	JJ	bullous	bullous	bullou	N	B-AdverseReaction
,	,	,	,	,	N	O
blistering	NN	blistering	blistering	blister	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
exfoliating	VBG	exfoliating	exfoliating	exfoli	N	B-AdverseReaction
lesions	NNS	lesions	lesion	lesion	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
0.15%	CD	0.15%	0.15%	0.15%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3865	CD	3865	3865	3865	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acneiform	VB	acneiform	acneiform	acneiform	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
90%	CD	90%	90%	90%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
16%	CD	16%	16%	16%	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
3	CD	3	3	3	N	I-Severity
palmar	NN	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
7%	CD	7%	7%	7%	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	VBG	threatening	threatening	threaten	N	O
bullous	JJ	bullous	bullous	bullou	N	O
,	,	,	,	,	N	O
blistering	NN	blistering	blistering	blister	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
exfoliating	VBG	exfoliating	exfoliating	exfoli	N	O
lesions	NNS	lesions	lesion	lesion	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
prolonged	VBN	prolonged	prolonged	prolong	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
lasting	VBG	lasting	lasting	last	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
,	,	,	,	,	N	O
intolerable	JJ	intolerable	intolerable	intoler	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
withhold	VBD	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
resolves	NNS	resolves	resolve	resolv	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
resume	VB	resume	resume	resum	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Interstitial	JJ	interstitial	interstitial	interstiti	N	O
Lung	NNP	lung	lung	lung	N	O
Disease	NNP	disease	disease	diseas	N	O
(	(	(	(	(	N	O
ILD	NNP	ild	ild	ild	N	O
)	)	)	)	)	N	O

ILD	NNP	ild	ild	ild	N	B-AdverseReaction
or	CC	or	or	or	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
lung	JJ	lung	lung	lung	N	B-AdverseReaction
infiltration	NN	infiltration	infiltration	infiltr	N	I-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
alveolitis	VB	alveolitis	alveolitis	alveol	Y	B-AdverseReaction
allergic	NN	allergic	allergic	allerg	N	I-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3865	CD	3865	3865	3865	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
;	:	;	;	;	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
,	,	,	,	,	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
were	VBD	were	were	were	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
higher	JJR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
Asian	JJ	asian	asian	asian	N	O
ethnicity	NN	ethnicity	ethnicity	ethnic	N	O
(	(	(	(	(	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
)	)	)	)	)	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
non	VB	non	non	non	N	O
-	:	-	-	-	N	O
Asians	NNPS	asians	asian	asian	N	O
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
and	CC	and	and	and	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
during	IN	during	during	dure	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
suspected	JJ	suspected	suspected	suspect	N	O
ILD	NNP	ild	ild	ild	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
ILD	NNP	ild	ild	ild	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

In	IN	in	in	in	N	O
3865	CD	3865	3865	3865	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
10.1%	CD	10.1%	10.1%	10.1%	N	O
had	VBD	had	had	had	N	O
liver	VBN	liver	liver	liver	N	B-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
0.18%	CD	0.18%	0.18%	0.18%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
liver	RB	liver	liver	liver	N	B-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
17.5%	CD	17.5%	17.5%	17.5%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
.	.	.	.	.	N	O

Obtain	NNP	obtain	obtain	obtain	N	O
periodic	JJ	periodic	periodic	period	N	O
liver	NN	liver	liver	liver	N	O
testing	VBG	testing	testing	test	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
worsening	VBG	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Keratitis	NNP	keratitis	keratitis	kerat	Y	O

Keratitis	NNP	keratitis	keratitis	kerat	Y	B-AdverseReaction
,	,	,	,	,	N	O
characterized	VBD	characterized	characterized	character	N	O
as	IN	as	a	as	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
eye	NN	eye	eye	eye	N	I-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
,	,	,	,	,	N	O
lacrimation	NN	lacrimation	lacrimation	lacrim	Y	B-AdverseReaction
,	,	,	,	,	N	O
light	JJ	light	light	light	N	B-AdverseReaction
sensitivity	NN	sensitivity	sensitivity	sensit	N	I-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
red	JJ	red	red	red	N	B-AdverseReaction
eye	NN	eye	eye	eye	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
among	IN	among	among	among	N	O
3865	CD	3865	3865	3865	N	O
patients	NNS	patients	patient	patient	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Keratitis	NN	keratitis	keratitis	kerat	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
during	IN	during	during	dure	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
suspected	JJ	suspected	suspected	suspect	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
ulcerative	JJ	ulcerative	ulcerative	ulcer	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
or	CC	or	or	or	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
keratitis	VBN	keratitis	keratitis	kerat	Y	O
is	VBZ	is	is	is	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
continuing	VBG	continuing	continuing	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
,	,	,	,	,	N	O
ulcerative	JJ	ulcerative	ulcerative	ulcer	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
dry	JJ	dry	dry	dri	N	O
eye	NN	eye	eye	eye	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Contact	NN	contact	contact	contact	N	O
lens	NNS	lens	lens	len	N	O
use	NN	use	use	use	N	O
is	VBZ	is	is	is	N	O
also	RB	also	also	also	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
factor	NN	factor	factor	factor	N	O
for	IN	for	for	for	N	O
keratitis	NN	keratitis	keratitis	kerat	Y	O
and	CC	and	and	and	N	O
ulceration	NN	ulceration	ulceration	ulcer	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Afatinib	NNP	afatinib	afatinib	afatinib	N	O
was	VBD	was	wa	wa	N	O
embryotoxic	JJ	embryotoxic	embryotoxic	embryotox	N	B-AdverseReaction
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	O
with	IN	with	with	with	N	O
maternal	JJ	maternal	maternal	matern	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
abortions	NNS	abortions	abortion	abort	N	B-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
late	JJ	late	late	late	N	I-AdverseReaction
gestational	JJ	gestational	gestational	gestat	N	I-AdverseReaction
stages	NNS	stages	stage	stage	N	I-AdverseReaction
in	IN	in	in	in	N	O
rabbits	NNS	rabbits	rabbit	rabbit	N	B-Animal
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
kg	FW	kg	kg	kg	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
0.2	CD	0.2	0.2	0.2	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
human	JJ	human	human	human	N	O
exposure	NN	exposure	exposure	exposur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
40	CD	40	40	40	N	O
mg	NNS	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
highly	RB	highly	highly	highli	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
become	VBP	become	become	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
GILOTRIF	NNP	gilotrif	gilotrif	gilotrif	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
and8	NN	and8	and8	and8	N	O
.	.	.	.	.	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

